Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) is reporting third quarter financial results on Monday 9th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, XERS is expected to report 3Q20 loss of $ 0.52 per share from revenue of $ 4.48 million.
For the full year, analysts anticipate top line of $ 14.86 million, while looking forward to loss of $ 2.49 per share bottom line.
Previous Quarter Performance
Xeris Pharmaceuticals, Inc. revealed loss for the second quarter of $ 0.63 per share, from the revenue of $ 2.03 million. The quarterly revenues elevated 534.38 percent compared with the same quarter last year. Wall street analysts are predicting, XERS to report 2Q20 loss of $ 0.73 per share from revenue of $ 1.86 million. The bottom line results beat street analysts by $ 0.1 or 13.70 percent, at the same time, top line results outshined analysts by $ 0.17 million or 9.14 percent.
Stock Performance
On Friday, shares of Xeris Pharmaceuticals, Inc. has traded high as $ 5.73 and has cracked $ 5.12 on the downward trend, reaching $ 5.45 with volume of 1.56 million shares.
According to the previous trading day, closing price of $ 5.45, representing a 280.99 % increase from the 52 week low of $ 1.42 and a 44.17 % decrease over the 52 week high of $ 9.69.
The company has a market capital of $ 252.23 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Xeris Pharmaceuticals, Inc. will be hosting a conference call at 8:30 AM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.xerispharma.com
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The companys lead product candidate is Gvoke HypoPen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes.
